The main objective of this project is the development of mucosal vaccines aimed at controlling infections associated with ETEC strains, one of the main etiologic agents of childhood diarrhea and traveler's diarrhea. Based formulations will be tested fimbriae purified and its subunit adhesive located in the apical region of the fimbriae. The vaccines are being tested plus two mucosal adjuvants, first, a nontoxic derivative of heat-labile toxin (LT) also produced by ETEC strains and, second, B. subtilis spores coadministered or adsorbed. The formulations are administered vaccines in mice by mucosal route, and the presence of specific antibodies is measured in samples of serum and mucosal extract (fecal and milk). Protective efficacy of antibodies generated will be determined in vitro for the ability to neutralize the adhesive properties of strains of ETEC. The work also provides the use of an animal model, based on neonatal mice, as a correlate of protection conferred by the vaccine against ETEC strains derived from human hosts. The results to be obtained should contribute to the development of new formulations vaccine against diarrhea associated with ETEC infections for clinical use and / or veterinarian.
News published in Agência FAPESP Newsletter about the scholarship: